Therapy of coronary heart disease - current standpoint: conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery)
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bremen [u.a.]
UNI-MED-Verl.
2010
|
| Ausgabe: | 1. ed. |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | 318 S. graph. Darst. |
| ISBN: | 9783837412314 9781848151611 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV026857977 | ||
| 003 | DE-604 | ||
| 005 | 20110228 | ||
| 007 | t | ||
| 008 | 110326s2010 d||| |||| 00||| eng d | ||
| 020 | |a 9783837412314 |9 978-3-8374-1231-4 | ||
| 020 | |a 9781848151611 |9 978-1-8481-5161-1 | ||
| 035 | |a (OCoLC)700052989 | ||
| 035 | |a (DE-599)GBV632145625 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-578 | ||
| 082 | 0 | |a 616.12306 |2 22/ger | |
| 084 | |a YB 9515 |0 (DE-625)153178:12921 |2 rvk | ||
| 084 | |a WG 300 |2 nlm | ||
| 100 | 1 | |a Strödter, Dietrich |e Verfasser |0 (DE-588)108228061 |4 aut | |
| 245 | 1 | 0 | |a Therapy of coronary heart disease - current standpoint |b conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) |c [Dietrich Strödter ; Frans Santosa] |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2010 | |
| 300 | |a 318 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Koronare Herzkrankheit |0 (DE-588)4073731-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Evidenz-basierte Medizin |0 (DE-588)4543414-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Koronare Herzkrankheit |0 (DE-588)4073731-7 |D s |
| 689 | 0 | 1 | |a Evidenz-basierte Medizin |0 (DE-588)4543414-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Santosa, Frans |e Sonstige |0 (DE-588)113400969 |4 oth | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022385935&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-022385935 | ||
Datensatz im Suchindex
| _version_ | 1804145492234338304 |
|---|---|
| adam_text | IMAGE 1
8 CONTENTS
CONTENTS
[I] FROM PRIMARY TO SECONDARY PREVENTION 16
1.1. DEFINITION 16
1.2. RISK FACTORS FOR ATHEROSCLEROSIS 17
1.3. AIMS OF SECONDARY PREVENTION 17
1.4. PRIMARY VERSUS SECONDARY PREVENTION 18
1.5. BLOOD PRESSURE/HBA LC GOALS 19
1.6. HBA, C TARGET IN DIABETICS 21
1.7. LIPIDS 21
1.8. NON-PHARMACOLOGICAL THERAPEUTIC MEASURES 22
1.9. SUMMARY 23
1.10. REFERENCES 23
[37] MANIFESTATIONS AND PROGNOSIS OF CAD 25
2.1. MANIFESTATIONS OF ATHEROSCLEROSIS 25
2.2. MANIFESTATIONS OF CAD 25
2.3. PROGNOSIS IN CAD 26
2.4. PROGNOSIS AND GENDER 27
2.5. PROGNOSIS IN RENAL INSUFFICIENCY 28
2.6. PROGNOSIS AND DIABETES 28
2.7. PROGNOSIS AND TYPE OF MEDICAL CARE 29
2.8. PROGNOSIS IN STEMI VERSUS NSTEMI 29
2.9. DECREASE IN CAD MORTALITY? 29
2.10. SUMMARY 30
2.11. REFERENCES 31
[3. J FROM THE ENDOTHELIAL DEFECT TO MYOCARDIAL INFARCTION 32
3.1. THE IMPORTANCE OF THE ENDOTHELIUM 32
3.2. THE ACETYLCHOLINE TEST AS A METHOD TO DEMONSTRATE ENDOTHELIAL
DYSFUNCTION 33
3.3. CLINICAL IMPACT OF ENDOTHELIAL DYSFUNCTION DURING STRESS 33
3.4. ENDOTHELIAL DYSFUNCTION AS A PROGNOSTIC INDICATOR 34
3.5. ENDOTHELIAL PROGENITOR CELLS 34
3.6. ATHEROSCLEROSIS IN THE CORONARY REGION 35
3.7. FROM ATHEROTHROMBOSIS TO THE ACUTE SYNDROME 37
3.8. REMODELLING OF THE LEFT VENTRICLE AFTER MYOCARDIAL INFARCTION 38
3.9. SUMMARY 33
3.10. REFERENCES 39
[AT] PATHOPHYSIOLOGY OF CAD AND STRATEGIES FOR SECONDARY PREVENTION 41
4.1. CORONARY INSUFFICIENCY 41
4.2. DETERMINANTS OF THE MYOCARDIAL O 2 REQUIREMENT 42
4.3. STRATEGIES FOR SECONDARY PREVENTION 42
BIBLIOGRAFISCHE INFORMATIONEN HTTP://D-NB.INFO/1009406973
DIGITALISIERT DURCH
IMAGE 2
CONTENTS 9
4.4. THERAPEUTIC PRIORITIES DEPENDING ON THE FORM OF PRESENTATION OF CHD
43
4.5. SUMMARY 44
4.6. REFERENCES 44
[5 . ] NITRATES AND OTHER ANTIANGINAL AGENTS 46
5.1. MECHANISM OF ACTION OF NITRATES 46
5.2. NITRATE DRUGS 46
5.3. DO NITRATES PROLONG SURVIVAL IN CAD? 47
5.4. NITRATES IN SECONDARY PREVENTION 48
5.5. MOLSIDOMINE 48
5.6. TRAPIDIL 48
5.7. POTASSIUM CHANNEL OPENERS (NICORANDIL) 49
5.8. RANOLAZINE 49
5.9. SUMMARY 50
5.10. REFERENCES 51
[6. I BETA-BLOCKERS 53
6.1. MECHANISM OF ACTION OF BETA-BLOCKERS 53
6.2. CLASSIFICATION OF BETA-BLOCKERS 53
6.3. DIFFERENCES BETWEEN BETA-BLOCKERS 53
6.4. TREATMENT AIMS ON BETA-BLOCKERS 54
6.5. BETA-BLOCKERS IN POST-INFARCT PATIENTS 54
6.6. WHO BENEFITS MOST? 55
6.7. DO AIL BETA-BLOCKERS HAVE A SECONDARY PREVENTION EFFECT? 57
6.8. CAN BETA-BLOCKERS BE USED FOR SECONDARY PREVENTION IN CAD WITHOUT
INFARCTION? 57
6.9. BETA-BLOCKERS IN HEART FAILURE 57
6.10. THIRD-GENERATION BETA-BLOCKERS 58
6.11. BETA-BLOCKERS IN LV DYSFUNCTION AFTER INFARCTION, THE CAPRICORN
STUDY 58
6.12. 2007 AHA/ACC GUIDELINES 59
6.13. THE 2008 ESC GUIDELINES 59
6.14. SUMMARY 59
6.15. REFERENCES 60
F7.3 CALCIUM ANTAGONISTS 62
7.1. MECHANISM OF ACTION OF CALCIUM ANTAGONISTS 62
7.2. DIFFERENCES BETWEEN THE CALCIUM ANTAGONISTS 62
7.3. CALCIUM ANTAGONISTS IN STABLE ANGINA 62
7.4. DIHYDROPYRIDINES IN POSTINFARCT PATIENTS 63
7.5. DILTIAZEM IN POSTINFARCT PATIENTS 63
7.6. VERAPAMIL IN POSTINFARCT PATIENTS 64
7.7. HYPERTENSIVE VERSUS NORMOTENSIVE POSTINFARCT PATIENTS 65
7.8. THIRD-GENERATION CALCIUM ANTAGONISTS IN CAD 65
7.9. SUMMARY 67
7.10. REFERENCES 68
IMAGE 3
10 CONTENTS
FJT] ACE INHIBITORS 70
8.1. MECHANISM OF ACTION 70
8.2. PATHOPHYSIOLOGICAL BASIS OF ACE INHIBITOR TREATMENT 70
8.3. ACE INHIBITORS AND ASPIRIN * 72
8.4. POSTINFARCTION STUDIES WITH ACE INHIBITORS 73
8.5. ACE INHIBITORS AND RISK OF ATRIAL FIBRILLATION 76
8.6. THE HOPE STUDY 76
8.7. ACE INHIBITORS AND RATE OF INFARCTION 78
8.8. ACE INHIBITORS IN ASSOCIATION WITH AND AFTER PTCA - THE QUIET STUDY
78
8.9. ACE INHIBITORS IN ASSOCIATION WITH AND AFTER CABG - THE QUO VADIS
STUDY 79
8.10. ACE INHIBITORS IN CAD PATIENTS WITH A LOWER RISK 79
8.11. 2006/2007 ACC/AHA GUIDELINES 81
8.12. SUMMARY 82
8.13. REFERENCES 82
[57] AT, RECEPTOR BLOCKERS 85
9.1. THE MECHANISM OF ACTION 85
9.2. AT, RECEPTOR BLOCKERS AND PLEIOTROPIC EFFECTS 85
9.3. CLINICAL STUDIES IN CAD 86
9.4. COMBINATION OF ACE INHIBITOR PLUS AT, RECEPTOR BLOCKER 89
9.5. 2006/2007 ACC/AHA- AND 2008 ESC-GUIDELINES 89
9.6. SUMMARY 89
9.7. REFERENCES 90
[TOE] STATINS (HMG-COA REDUCIASE INHIBITORS) 91
10.1. SITUATION BEFORE THE STATIN ERA 91
10.2. MECHANISM OF ACTION OF THE STATINS 91
10.3. A COMPARISON OF STATINS 91
10.4. STATINS AND DOSE-EFFECT RELATIONSHIP 93
10.5. STATINS IN SECONDARY PREVENTION - THE EVIDENCE FROM STUDIES 93
10.6. THE TIME FOR USING AN HMG-COA REDUCIASE INHIBITOR DURING AND AFTER
ACUTE CORONARY SYNDROME 98
10.7. STATINS AND NUMBER OF REVASCULARISATIONS 98
10.8. ACE INHIBITORS AFTER CABG AND PTCA 99
10.9. HMG-COA REDUCTASE INHIBITORS IN PTCA 100
10.10. WHO BENEFITS FROM LDL LOWERING? YOUNGER OR OLDER PATIENTS? 101
10.11. ADDITIONAL VASCULAR EFFECTS OF HMG-COA REDUCTASE INHIBITORS 102
10.12. LDL LOWERING AND CARDIAC RISK - THE GREATER THE LDL REDUCTION,
THE BETTER 107
10.13. LDL TREATMENT TARGETS TODAY 110
10.14. STATINS IN HIGH-RISK PATIENTS 112
10.15. FIBRATES IN SECONDARY PREVENTION 113
10.16. 2006/2007 ACC/AHA GUIDELINES 114
10.17. SUMMARY 115
10.18. REFERENCES 115
IMAGE 4
CONTENTS 11
[TT] ANTIPLATELET AGENTS 119
11.1. ANTIPLATELET AGENTS - AN OVERVIEW 119
11.2. MECHANISM OF ACTION OF ANTIPLATELET AGENTS 119
11.3. MOLECULAR TARGET OF THE THIENOPYRIDINES 120
11.4. PRASUGREL VERSUS CLOPIDOGREL 120
11.5. CLOPIDOGREL AND INTERACTION WITH PPIS 121
11.6. REBOUND PHENOMENA AND RESISTANCE 122
11.7. TICAGRELOR AND CANGRELOR 123
11.8. GLYCOPROTEIN LLB/LLLA RECEPTOR INHIBITORS 123
11.9. ASPIRIN (ACETYLSALICYLIC ACID, ASS) 123
11.10. ASPIRIN PLUS LOW-DOSE COUMARINS 125
11.11. CLOPIDOGREL 126
11.12. CLOPIDOGREL PLUS ASPIRIN 127
11.13. ORAL GLYCOPROTEIN LLB/LLLA RECEPTOR INHIBITORS 131
11.14. CURRENT GUIDELINES 131
11.15. SUMMARY 133
11.16. REFERENCES 133
JJ2J ANTICOAGULANTS 137
12.1. THE SIXTY PLUS STUDY IN THE ELDERLY 137
12.2. THE WARIS-1 STUDY 137
12.3. THE ASPECT-1 STUDY 137
12.4. THE ASPECT-2 STUDY 138
12.5. THE WARIS-2 STUDY 138
12.6. THE APRICOT-2 STUDY 138
12.7. INDICATIONS FOR COUMARINS TODAY 138
12.8. ANTITHROMBOTIC TREATMENT IN ATRIAL FIBRILLATION 139
12.9. DABIGATRAN IN ATRIAL FIBRILLATION - THE RE-LY STUDY 141
12.10. SUMMARY 142
12.11. REFERENCES 142
[13J ANTIHYPERTENSIVE AGENTS 144
13.1. HYPERTENSION AND RISK IN CAD 144
13.2. THE HOPE STUDY 144
13.3. SUBGROUP ANALYSIS OF THE CAD PATIENTS IN THE HOT STUDY 144
13.4. ISOLATED SYSTOLIC HYPERTENSION (ISH) 145
13.5. THE RENAAL STUDY AND IDNT STUDY 145
13.6. THE INVEST STUDY 145
13.7. THE VALUE STUDY 146
13.8. BLOOD PRESSURE VERSUS CHANGE IN PLAQUE SIZE 146
13.9. WHICH COMBINATION THERAPY - THE ACCOMPLISH STUDY 147
13.10. TARGET BLOOD PRESSURE VALUES IN CAD 148
13.11. CALCIUM ANTAGONISTS PLUS ACE INHIBITORS IN CHRONIC STABLE CAD 148
13.12. SUMMARY 149
13.13. REFERENCES 149
IMAGE 5
12 CONTENTS
[14J OMEGA-3 FATTY ACIDS 150
14.1. THE GISSI PREVENTION STUDY 150
14.2. RECOMMENDATIONS OF THE ESC, AHA, NICE 151
14.3. THE OMEGA STUDY 152
14.4. SUMMARY 152
14.5. REFERENCES 152
[IS] IVABRADINE, THE I, CHANNEL BLOCKER 154
15.1. THE BEAUT/ FUL STUDY 154
15.2. SUMMARY 155
15.3. REFERENCES 155
P E L] UNSTABLE ANGINA PECTORIS/NON-Q-WAVE INFARCTION (NSTEMI) 157
16.1. DEFINITION 157
16.2. THE PROGNOSIS IN UNSTABLE ANGINA/NON-Q-WAVE INFARCTION 157
16.3. AIMS OF TREATMENT 158
16.4. NITRATES IN UNSTABLE ANGINA/NON-Q-WAVE INFARCTION 158
16.5. BETA-BLOCKERS 158
16.6. CALCIUM ANTAGONISTS 159
16.7. ASPIRIN 159
16.8. HEPARIN IN UNSTABLE ANGINA/NSTEMI 159
16.9. PENTASACCHARIDES 161
16.10. BIVALIRUDIN 161
16.11. GP LLB/LLLA RECEPTOR INHIBITORS IN UNSTABLE ANGINA 161
16.12. CLOPIDOGREL PLUS ASPIRIN IN UNSTABLE ANGINA/NON-Q-WAVE INFARCTION
163
16.13. PRASUGREL VERSUS CLOPIDOGREL 167
16.14. STATINS IN ACUTE CORONARY SYNDROME 172
16.15. INVASIVE VERSUS NON-INVASIVE APPROACH IN UNSTABLE ANGINA/NSTEMI
174
16.16. THE IMPORTANCE OF GP LLB/LLLA RECEPTOR INHIBITORS IN PCI 177
16.17. THE COMBINATION OF GP LLB/LLLA INHIBITORS, ASPIRIN, HEPARIN,
CLOPIDOGREL 178
16.18. IMPROVEMENT IN PROGNOSIS IN NSTE-ACS 178
16.19. APPROACH IN UNSTABLE ANGINA/NSTEMI (2007/2009 ESC AND ACC/AHA
GUIDELINES) 178
16.20. ALGORITHM IN THE CASE OF ACS - 2007 ESC GUIDELINES 182
16.21. THE GRACE RISK SCORE 182
16.22. TICAGRELOR IN ACS 182
16.23. SUMMARY 184
16.24. REFERENCES 186
[17] THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION (STEM1) 190
17.1. THE EFFECT OF THROMBOLYSIS 190
17.2. ASPIRIN 193
17.3. CLOPIDOGREL 195
17.4. PRASUGREL VS CLOPIDOGREL IN STEMI - THE TRITON-TIMI 38 STUDY 196
17.5. ANTICOAGULATION 197
17.6. NITRATES 198
IMAGE 6
CONTENTS 13
17.7. BETA-BLOCKERS 200
17.8. ACE INHIBITORS/AT, RECEPTOR BLOCKERS 201
17.9. AT, RECEPTOR BLOCKERS 203
17.10. CALCIUM ANTAGONISTS 203
17.11. ANTIARRHYTHMICS (LIDOCAINE PROPHYLAXIS) 203
17.12. PTCA IN ACUTE INFARCTION (STEMI) 203
17.13. LYSIS VERSUS TRANSPORT TO A PCI CENTRE 204
17.14. PTCA VERSUS PTCA PLUS STENT 205
17.15. PTCA PLUS STENT PLUS GP LLB/LLLA INHIBITOR 205
17.16. RESCUE PCI/FACILITATED PCI 206
17.17. NATIONAL DIFFERENCES IN THE HOSPITALISATION TIME 207
17.18. THE PROGNOSIS IN STEMI 207
17.19. THE NEW CLASSIFICATION OF INFARCTION 207
17.20. 2009 AND 2008 GUIDELINES OF THE ACC/AHA AND ESC 207
17.21. DES VERSUS BMS IN STEMI - THE HORIZONS-AMI STUDY 209
17.22. SUMMARY 209
17.23. REFERENCES 211
[I8.J ELECTIVE REVASCULARISATION PROCEDURES IN CAD 216
18.1. BYPASS SURGERY 216
18.2. PTCA 218
18.3. STENTS 219
18.4. PTCA VERSUS CABG 222
18.5. PTCA VERSUS ATHERECTOMY 223
18.6. TRANSMYOCARDIAL LASER REVASCULARISATION 224
18.7. BETA-BLOCKERS BEFORE CABG 225
18.8. CORONARY ANGIOGRAPHY VERSUS FRACTIONAL FLOW RESERVE AS A PARAMETER
FOR INDICATING PCI - THE FAME STUDY 225
18.9. SURGICAL VENTRICLE RECONSTRUCTION - THE STICH STUDY 225
18.10. ADHERENCE TO GUIDELINES FOR PCI AND CABG 226
18.11. MEASURES IN REFRACTORY ANGINA 226
18.12. CABG VERSUS MINIMALLY INVASIVE SURGERY 227
18.13. SUMMARY 227
18.14. REFERENCES 228
[I9J CONSERVATIVE THERAPY VERSUS INTERVENTIONAL/SURGICAL THERAPY 232
19.1. CURRENT SECONDARY PREVENTION AND TARGETS 232
19.2. ADDITIVE EFFECTS WITH FOUR SECONDARY PREVENTION AGENTS? 232
19.3. INDIVIDUAL CONSERVATIVE MEASURES IN CHRONIC STABLE CAD VERSUS PCI
235
19.4. OPTIMISED SECONDARY PREVENTION VERSUS PCI WITH STENT 236
19.5. IS LATE REPERFUSION WORTH WHILE? THE OPEN ARTERY HYPOTHESIS 238
19.6. OPTIMISED SECONDARY PREVENTION VS PCI IN DIABETES - THE BARI 2D
STUDY 238
19.7. META-ANALYSES ON OPTIMISED SECONDARY PREVENTION VS PCI 239
IMAGE 7
14 CONTENTS
19.8. NO SUCCESSES WITH LOW RISK 240
19.9. CONSERVATIVE VERSUS INTERVENTIONAL/SURGICAL THERAPY 241
19.10. THE PROBLEM ANDA SUGGESTED SOLUTION 242
19.11. COURAGE AND WALL STREET - A CONTROVERSIAL SUBJECT 242
19.12. SUMMARY: PRIORITISING BEFORE RATIONING 244
19.13. SUMMARY 244
19.14. REFERENCES 245
[2O3 POSTINFARCTION FAILURE 248
20.1. PATHOPHYSIOLOGICAL BACKGROUND 248
20.2. SPIRONOLACTONE IN NYHA CLASS III AND IV 248
20.3. EPLERENONE AFTER ACUTE MYOCARDIAL INFARCTION WITH LV DYSFUNCTION
248
20.4. GUIDELINES ON ALDOSTERONE ANTAGONISTS AFTER MYOCARDIAL INFARCTION
249
20.5. 2006/2007 ACC/AHA GUIDELINES AND 2008 ESC GUIDELINES 249
20.6. SUMMARY 250
20.7. REFERENCES 250
|2JJ ANTIARRHYTHMIC DRUGS 251
21.1. PATHOPHYSIOLOGICAL BACKGROUND 251
21.2. THE PRO-ARRHYTHMOGENIC EFFECT IN RELATION TO THE EJECTION FRACTION
251
21.3. CLINICAL STUDIES IN VENTRICULAR EXTRASYSTOLES 251
21.4. AMIODARONE IN HEART FAILURE 252
21.5. AMIODARONE IN POST-INFARCT PATIENTS 253
21.6. ANTIARRHYTHMICS IN ATRIAL FIBRILLATION 254
21.7. SUMMARY 259
21.8. REFERENCES 260
[22] ICD, CRT, CARDIAC PACEMAKERS 262
22.1. THE MPLANTABLE DEFIBRILLATOR (ICD) 262
22.2. RESYNCHRONISATION THERAPY (CRT) 268
22.3. PROGRAMMED STIMULATION FOR RISK IDENTIFICATION 272
22.4. CARDIAC PACEMAKER THERAPY 272
22.5. SUMMARY 273
22.6. REFERENCES 274
[23J LIFESTYLE, BODY WEIGHT, SMOKING, ALCOHOL, PHYSICAL ACTIVITY AND
REHABILITATION 277
23.1. DIET 277
23.2. NORMALISATION OF BODY WEIGHT 279
23.3. SMOKING 281
23.4. ALCOHOL 284
23.5. PHYSICAL ACTIVITY AND REHABILITATION 287
23.6. WHEN SHOULD LIFESTYLE CHANGES BEGIN? 289
23.7. SUMMARY 289
23.8. REFERENCES 290
IMAGE 8
CONTENTS 15
|24J HDL, TRIGLYCERIDES, LP(A), THE FORGOTTEN LIPID FRACTIONS 294
24.1. HYPERLIPOPROTEINAEMIAS, AN OVERVIEW 294
24.2. ASSOCIATIONS BETWEEN LIPIDS 294
24.3. LIPID-LOWERING DRUGS 296
24.4. HDL 296
24.5. TRIGLYCERIDES 301
24.6. WHAT DO THE GUIDELINES SAY? 305
24.7. LIPOPROTEIN (A) 306
24.8. ALL LIPID FRACTIONS ARE IMPORTANT 307
24.9. SUMMARY 307
24.10. LITERATUR 309
[25.] ABBREVIATIONS 312
F~ ] INDEX 314
|
| any_adam_object | 1 |
| author | Strödter, Dietrich |
| author_GND | (DE-588)108228061 (DE-588)113400969 |
| author_facet | Strödter, Dietrich |
| author_role | aut |
| author_sort | Strödter, Dietrich |
| author_variant | d s ds |
| building | Verbundindex |
| bvnumber | BV026857977 |
| classification_rvk | YB 9515 |
| ctrlnum | (OCoLC)700052989 (DE-599)GBV632145625 |
| dewey-full | 616.12306 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12306 |
| dewey-search | 616.12306 |
| dewey-sort | 3616.12306 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01668nam a2200409 c 4500</leader><controlfield tag="001">BV026857977</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20110228 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">110326s2010 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837412314</subfield><subfield code="9">978-3-8374-1231-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781848151611</subfield><subfield code="9">978-1-8481-5161-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)700052989</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV632145625</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-578</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12306</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 9515</subfield><subfield code="0">(DE-625)153178:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WG 300</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Strödter, Dietrich</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)108228061</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapy of coronary heart disease - current standpoint</subfield><subfield code="b">conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery)</subfield><subfield code="c">[Dietrich Strödter ; Frans Santosa]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">318 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Koronare Herzkrankheit</subfield><subfield code="0">(DE-588)4073731-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Evidenz-basierte Medizin</subfield><subfield code="0">(DE-588)4543414-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Koronare Herzkrankheit</subfield><subfield code="0">(DE-588)4073731-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Evidenz-basierte Medizin</subfield><subfield code="0">(DE-588)4543414-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santosa, Frans</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)113400969</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022385935&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-022385935</subfield></datafield></record></collection> |
| id | DE-604.BV026857977 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T23:20:18Z |
| institution | BVB |
| isbn | 9783837412314 9781848151611 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-022385935 |
| oclc_num | 700052989 |
| open_access_boolean | |
| owner | DE-578 |
| owner_facet | DE-578 |
| physical | 318 S. graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Strödter, Dietrich Verfasser (DE-588)108228061 aut Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) [Dietrich Strödter ; Frans Santosa] 1. ed. Bremen [u.a.] UNI-MED-Verl. 2010 318 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED science Koronare Herzkrankheit (DE-588)4073731-7 gnd rswk-swf Evidenz-basierte Medizin (DE-588)4543414-1 gnd rswk-swf Koronare Herzkrankheit (DE-588)4073731-7 s Evidenz-basierte Medizin (DE-588)4543414-1 s DE-604 Santosa, Frans Sonstige (DE-588)113400969 oth DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022385935&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Strödter, Dietrich Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) Koronare Herzkrankheit (DE-588)4073731-7 gnd Evidenz-basierte Medizin (DE-588)4543414-1 gnd |
| subject_GND | (DE-588)4073731-7 (DE-588)4543414-1 |
| title | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) |
| title_auth | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) |
| title_exact_search | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) |
| title_full | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) [Dietrich Strödter ; Frans Santosa] |
| title_fullStr | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) [Dietrich Strödter ; Frans Santosa] |
| title_full_unstemmed | Therapy of coronary heart disease - current standpoint conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) [Dietrich Strödter ; Frans Santosa] |
| title_short | Therapy of coronary heart disease - current standpoint |
| title_sort | therapy of coronary heart disease current standpoint conservative medical therapy vs ptca stent and cabg bypass surgery |
| title_sub | conservative medical therapy vs. PTCA/STENT and CABG (bypass surgery) |
| topic | Koronare Herzkrankheit (DE-588)4073731-7 gnd Evidenz-basierte Medizin (DE-588)4543414-1 gnd |
| topic_facet | Koronare Herzkrankheit Evidenz-basierte Medizin |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022385935&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT strodterdietrich therapyofcoronaryheartdiseasecurrentstandpointconservativemedicaltherapyvsptcastentandcabgbypasssurgery AT santosafrans therapyofcoronaryheartdiseasecurrentstandpointconservativemedicaltherapyvsptcastentandcabgbypasssurgery |